As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at…
New research indicates that treatment with the investigational anti-amyloid drug Tarenflurbil appears to be well-tolerated in patients with mild to moderate Alzheimer’s disease and may exert a dose-related…
In a recent study, fluoxetine (Prozac) decreased progression of relapsing-remitting MS in a small placebo-controlled study, but the effect lasted only a few months. References and Resources Mostert…
A tablet that combines sumatriptan and naproxen (Treximet) has been approved by the FDA for treatment of migraine with and without aura. References and Resources FDA Sponsored by…
Greg Foltz, MD, Director, Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, discusses current treatments for brain cancer. References and Resources Schönekaes K, Mücke R,…
Rituximab failed to meet the primary endpoint of stemming the progression of primary-progressive multiple sclerosis (PPMS) in a Phase II/III trial. From Our Partners at VerusMed verusmed.com Sponsored…
At the American Academy of Neurology meeting, researchers gave final results of the phase III PRECISE trial of glatiramer acetate (Copaxone), which delayed the onset of clinically confirmed…
The American College of Physicians and the American Academy of Family Physicians issued clinical practice guidelines about the pharmacologic treatment of dementia. From our partners at VerusMed verusmed.com…
In BMC Neurology it is reported that pesticide exposure may boost the risk of developing Parkinson’s disease over and above genetic factors. References and Resources Hancock D, Martin…
An open randomized trial showed that for a first episode of schizophrenia, four second-generation antipsychotics were no more effective than haloperidol, but they did have lower discontinuation rates.…